COSCIENS Biopharma Overview
Latest ROE for COSCIENS Biopharma: -265.34% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-265.34%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
COSCIENS Biopharma (CSCI) currently reports a ROE of -265.34%. That is below the sector sector average of -4.03%. Use the charts on this page to explore COSCIENS Biopharma's ROE history and peer comparisons.
COSCIENS Biopharma's ROE of -265.34% is lower than the its sector sector average of -4.03%. That is roughly 6492.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but COSCIENS Biopharma's current -265.34% should be judged against industry norms (sector average: -4.03%) and against CSCI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -265.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -4.03%. From there, open related valuation or income-statement pages for COSCIENS Biopharma, and consider following CSCI for alerts when major investors trade the stock.
